数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮亏损失约51.83万 元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益1.83%，同 类排名6888/8861；近一年收益7.03%，同类排名6921/8126；成立以来收益72.96%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 1月27日，舒泰神跌5.2%，截至发稿，报26.60元/股，成交3.83亿元，换手率3.13%，总市值127.09亿 元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 朱慧灵累计任职时间301天，现任基金资产总规模2.42亿元 ...

Group 1 - The core viewpoint of the news is that Shuyou Shen's stock has shown a significant increase in price recently, with a year-to-date increase of 10.65% and a notable rise of 10.65% over the last five trading days [1] - As of January 9, Shuyou Shen's stock price reached 30.23 yuan per share, with a total market capitalization of 14.443 billion yuan [1] - The company primarily engages in the research, production, and sales of biological products and certain chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] Group 2 - As of September 30, the number of shareholders for Shuyou Shen increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, but has not paid any dividends in the last three years [3]

Group 1 - The core viewpoint of the news is that Shutaishen's stock has shown significant volatility, with a year-to-date increase of 275.17% and recent fluctuations in trading volume and price [1][2] - As of December 25, Shutaishen's stock price was 27.80 yuan per share, with a total market capitalization of 13.282 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 23.4642 million yuan, with large orders showing a buy-sell imbalance [1] Group 2 - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the primary revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] - As of September 30, the company reported a revenue of 181 million yuan for the first nine months of 2025, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.6895 million yuan, a decrease of 227.71% [2] - The company has not distributed any dividends in the last three years, with a total payout of 771 million yuan since its A-share listing [3]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

截至发稿，王晓川累计任职时间3年192天，现任基金资产总规模20.2亿元，任职期间最佳基金回报 66.28%， 任职期间最差基金回报2.75%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 数据显示，银华基金旗下1只基金重仓舒泰神。银华成长智选混合A（024455）三季度持有股数43.03万 股，占基金净值比例为3.48%，位居第九大重仓股。根据测算，今日浮盈赚取约67.99万元。 银华成长智选混合A（024455）成立日期2025年6月20日，最新规模2.53亿。成立以来收益5.31%。 银华成长智选混合A（0244 ...

数据显示，东方阿尔法基金旗下1只基金重仓舒泰神。东方阿尔法健康产业混合发起A（024357）三季 度增持22.3万股，持有股数23.95万股，占基金净值比例为6.08%，位居第八大重仓股。根据测算，今日 浮亏损失约39.51万元。连续5天下跌期间浮亏损失176.72万元。 东方阿尔法健康产业混合发起A（024357）成立日期2025年6月12日，最新规模3539.51万。成立以来亏 损4.69%。 东方阿尔法健康产业混合发起A（024357）基金经理为孟昱。 11月24日，舒泰神跌5.17%，截至发稿，报30.27元/股，成交3.80亿元，换手率2.67%，总市值144.62亿 元。舒泰神股价已经连续5天下跌，区间累计跌幅18.78%。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 截至发稿，孟昱累计任 ...

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 426.05%, but recent performance indicates a mixed trend with a decline over the past 60 days [2]. Group 1: Stock Performance - As of November 14, Shuyou Shen's stock price rose by 2.04% to 38.98 CNY per share, with a trading volume of 9.15 billion CNY and a market capitalization of 186.24 billion CNY [1]. - The stock has experienced a 14.71% increase over the last five trading days, but a 2.31% decrease over the last 20 days and a 23.54% decline over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decrease of 227.71% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 771 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Xingquan Helun Mixed A and an increase by Xingquan Heyi Mixed A [3].

Core Insights - Shuyou Shen's stock price increased by 5.08% on November 13, reaching 39.12 CNY per share, with a trading volume of 1.698 billion CNY and a turnover rate of 10.05%, resulting in a total market capitalization of 18.69 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 9.56% during this period [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011 [1] - The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - Main revenue sources include: 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Fund Holdings - CITIC Prudential Fund holds a significant position in Shuyou Shen, with the CITIC Prudential Zhi Rui Mixed A Fund (003432) owning 295,000 shares, accounting for 3.99% of the fund's net value, making it the eighth-largest holding [2] - The fund has realized a floating profit of approximately 557,600 CNY today and 958,800 CNY during the three-day increase [2] Fund Manager Performance - The fund manager Wang Rui has a tenure of 10 years and 201 days, with a total fund size of 6.438 billion CNY and a best return of 253.09% during his tenure [3] - Liu Hongliang has been managing the fund for 1 year and 121 days, with a fund size of 2.693 billion CNY and a best return of 9.67% [3] - Zhu Huiling has a shorter tenure of 226 days, managing a fund size of 259 million CNY, with a best return of 8.63% [3]

Group 1 - The core viewpoint of the news is that Shuotai Shen's stock price increased by 5.66%, reaching 39.00 CNY per share, with a trading volume of 1.576 billion CNY and a turnover rate of 9.24%, resulting in a total market capitalization of 18.633 billion CNY [1] - Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shuotai Shen includes: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of the top ten holdings of funds, the Dongfang Alpha Fund has a significant position in Shuotai Shen, with the Dongfang Alpha Health Industry Mixed Fund A (024357) increasing its holdings by 223,000 shares, totaling 239,500 shares, which accounts for 6.08% of the fund's net value, ranking as the eighth largest holding [2] - The Dongfang Alpha Health Industry Mixed Fund A (024357) was established on June 12, 2025, with a latest scale of 35.3951 million CNY. Since its inception, it has experienced a loss of 3.88% [2] - The fund manager of Dongfang Alpha Health Industry Mixed Fund A is Meng Yu, who has been in the position for 1 year and 350 days, with total assets of 306 million CNY. The best fund return during his tenure is 18.12%, while the worst return is -4.04% [2]